Amneal Pharmaceuticals (NASDAQ:AMRX) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of Amneal Pharmaceuticals (NASDAQ:AMRX) from a hold rating to a strong sell rating in a report released on Tuesday morning,Zacks reports.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $22.00 target price on shares of Amneal Pharmaceuticals in a research note on Wednesday, August 26th. Barclays increased their price target on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, September 17th. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 26th. UBS Group reiterated a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Finally, Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $21.00.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock opened at $19.65 on Tuesday. The stock’s fifty day moving average is $18.42 and its 200-day moving average is $15.90. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20. The stock has a market capitalization of $6.28 billion, a PE ratio of 40.10, a PEG ratio of 2.31 and a beta of 1.22. Amneal Pharmaceuticals has a 52 week low of $9.56 and a 52 week high of $21.17.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%.Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities research analysts expect that Amneal Pharmaceuticals will post 0.95 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other news, EVP Nikita Shah sold 146,403 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the transaction, the executive vice president owned 253,390 shares in the company, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jason Daly sold 210,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the transaction, the executive vice president owned 35,171 shares of the company’s stock, valued at $611,975.40. This represents a 85.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 413,016 shares of company stock valued at $7,216,567 over the last 90 days. 17.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AMRX. GAMMA Investing LLC lifted its stake in Amneal Pharmaceuticals by 54.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,605 shares of the company’s stock valued at $32,000 after acquiring an additional 569 shares in the last quarter. Arizona State Retirement System grew its stake in shares of Amneal Pharmaceuticals by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 44,011 shares of the company’s stock worth $762,000 after acquiring an additional 837 shares in the last quarter. Hsbc Holdings PLC grew its stake in shares of Amneal Pharmaceuticals by 1.6% during the 4th quarter. Hsbc Holdings PLC now owns 101,945 shares of the company’s stock worth $1,297,000 after acquiring an additional 1,569 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Amneal Pharmaceuticals in the second quarter valued at approximately $29,000. Finally, Handelsbanken Fonder AB raised its holdings in shares of Amneal Pharmaceuticals by 3.0% in the second quarter. Handelsbanken Fonder AB now owns 76,400 shares of the company’s stock valued at $1,322,000 after purchasing an additional 2,200 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a global pharmaceutical company that develops, manufactures and markets a broad portfolio of generic and specialty medicines. The company focuses on complex and difficult-to-manufacture products, including injectables, biosimilars, ophthalmic medicines, respiratory treatments, oncology products, transdermal formulations and other dosage forms.

Amneal also operates a specialty pharmaceutical business focused on branded products in areas such as central nervous system disorders, endocrinology and other therapeutic categories.